about
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients.Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome.Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients.Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia.Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemiaIdentification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use.Adult T-cell acute lymphoblastic leukemia: prognostic impact of myeloid-associated antigens.Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool.On the potential involvement of CD11d in co-stimulating the production of interferon-γ by natural killer cells upon interaction with neutrophils via intercellular adhesion molecule-3.Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells.Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.Immunophenotypic analysis of hematopoiesis in patients suffering from Shwachman-Bodian-Diamond Syndrome.A quantitative study of growth variability of tumour cell clones in vitro.Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia.Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naïve chronic lymphocytic leukemiaHow much specific is the association between hymenoptera venom allergy and mastocytosis?Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosisClonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.Effects of wheat germ agglutinin on human gastrointestinal epithelium: insights from an experimental model of immune/epithelial cell interaction.Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells.Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders.Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy.Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis.Human neutrophils interact with both 6-sulfo LacNAc+ DC and NK cells to amplify NK-derived IFN{gamma}: role of CD18, ICAM-1, and ICAM-3.Neutrophil activation and survival are modulated by interaction with NK cells.The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.Up-regulation of CXCL8/interleukin-8 production in response to CXCL12 in chronic lymphocytic leukemia.Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF- B and JNK/AP-1 pathwaysZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factorOutcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemiaInterleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stromaAbsence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial
P50
Q33390369-CA6E95B0-5F1D-4FA5-A530-F4DDA10614DBQ33430911-CA843B71-0DC6-45CB-B223-6E45964A2417Q33431360-E5AFECB4-C5B6-4ED3-869E-46EC040F0590Q33558719-C81CA9C9-C735-4553-81A9-7EF481A55E1AQ36544769-DC19D2C4-8DDE-4D04-BDA7-E0E06953FC52Q36550468-6A72CF00-3942-4284-B270-0275074936C9Q37225379-41001735-4B7C-4755-8706-536FF0744F71Q37317367-BAD63831-AB3A-4A54-A4E0-1B12DC4E2EE1Q37602625-D0827463-324C-433C-87CC-D6F23B07F83EQ37810105-BCE50288-4C83-4DB9-AF99-9D97689E0C84Q38205501-A0C63C15-9FD4-479F-8E2C-30E99F250679Q38621013-2DB3B889-9B6E-48D3-8D51-EE75DCC99CB9Q38911110-894CBE76-F45E-43F9-929B-49E65B05E61DQ39059693-27FD6368-FC8B-4368-B2F6-4F7714EBF74BQ39097198-2A4D4DC7-6314-40F0-A109-E25090335C34Q40022104-2A30F731-E54C-4591-AEEF-672072F01AEEQ40147208-E1583B2F-12FC-47CE-9AF0-B3B2852C90C1Q42361910-FACE73BB-5DF3-44FD-9BE1-890C67D3B6D0Q42457384-ED3D393D-5710-45FE-88BB-F7898321899DQ42639038-4274899C-2958-446C-B220-CA5BEC108D80Q43992711-2A26CB14-54F3-434E-A4D4-65808DBCE8B5Q44767953-696BFF90-55D0-4B6D-94C3-3357BB099E18Q46068978-FC0DA0FE-683C-49F6-8E8D-BAA1E1D93D96Q46219221-6436979D-69C5-4FED-A6ED-3103250CBD21Q46333840-F5B8C9B1-8B21-4BC9-A01D-B3E8FA862751Q47584723-1930ADAA-033E-4F63-BCD7-4B77BDE87A67Q50214509-218F207A-5F01-44B8-9B47-43E5E8BA2B2EQ50484927-6B4D524D-3147-4B0D-92F3-B88821573630Q51307682-DFF90916-11EC-480A-9C63-C5CD1451618AQ52687815-A61DE058-B075-434B-A133-9E332A8451DAQ52750513-72651C1F-C6C8-433A-9AF4-984CABD655B6Q53287832-A8BBE27C-ED40-4BB9-8430-FE4AC8D9AAF3Q53304154-3501715A-768F-487D-B4CB-EC01E5F765D1Q54177638-103EDE59-176C-4A0C-B1BD-89FCB4C2BF09Q54187258-83C464E0-A5BF-4623-8521-B632473D78BAQ57425916-FEFDB427-4433-4A4C-8119-36126398F195Q58042045-4EFF19AD-D452-4C7D-BD9D-F131F3AA282CQ78691313-C2066ED2-A082-408A-B224-8BA638C29855Q79765253-50EA6996-411F-4643-9F3D-2A6B3D1C07C7Q79879700-E9265B23-B2E7-4AD9-B255-1D014E9467AD
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Omar Perbellini
@ast
Omar Perbellini
@en
Omar Perbellini
@es
Omar Perbellini
@nl
type
label
Omar Perbellini
@ast
Omar Perbellini
@en
Omar Perbellini
@es
Omar Perbellini
@nl
prefLabel
Omar Perbellini
@ast
Omar Perbellini
@en
Omar Perbellini
@es
Omar Perbellini
@nl
P106
P1153
6506804005
P21
P31
P496
0000-0002-8278-8916